CONTENTS:
News from the 2016 American Society of Hematology (ASH) Annual Meeting
- Learning More about Current ITP Treatments:
- Several Important Factors Determine Physicians’ Treatment Decisions in Selecting Second-Line Therapies for Children with ITP
- Eltrombopag When Compared to Rituximab Improved the Probability of Response in Chronic ITP Adult Patients
- Eltrombopag, Low-Dose Rituximab, and High-Dose Dexamethasone Combination Works Well as First Line Treatment for Newly Diagnosed ITP Patients
- Understanding More about TPO Treatments:
- Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with ITP Finds 80% of Children Had a Platelet Response Over the Course of the Study
- Patient-Reported Health-Related Quality of Life Improves over Time in Patients with Chronic Immune Thrombocytopenia Receiving Long-Term Treatment with Eltrombopag
- Splenectomy Findings: